false
0001640266
0001640266
2026-07-13
2026-07-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): July 13, 2026
Voyager
Therapeutics, Inc.
(Exact name of
registrant as specified in its charter)
| Delaware |
|
001-37625 |
|
46-3003182 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
75 Hayden Avenue
Lexington,
Massachusetts |
|
02421 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s telephone number,
including area code (857) 259-5340
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
| Common
Stock, $0.001 par value |
VYGR |
Nasdaq
Global Select Market |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
On July 13, 2026, Voyager Therapeutics, Inc. (the “Company”)
presented good laboratory practice (“GLP”) toxicology data for VY1706, the Company’s investigational tau silencing gene
therapy developed to target intracellular and extracellular tau for Alzheimer’s disease (“AD”), at the Alzheimer’s
Association International Conference.
The three- and six-month GLP toxicology data presented demonstrated
a favorable tolerability profile for VY1706 in non-human primates (“NHPs”) in the study, with no adverse clinical pathology
or histopathological findings observed in the central nervous system (“CNS”), dorsal root ganglia, and peripheral organs (including
liver) up to the highest dose tested of 5 x 1013 vector genomes / kilogram. The GLP data also showed a single intravenous dose
of VY1706 in NHPs achieved broad, durable, and dose-dependent CNS delivery with up to 75% lowering of microtubule-associated protein tau
(MAPT) mRNA and tau protein in key AD-relevant brain regions through six months. Additionally, ALPL, a well-conserved brain vasculature
endothelial receptor, was shown to mediate VY1706 blood-brain barrier transport in the study, supporting the potential for cross-species
translatability.
As previously disclosed, the Company received U.S. Food and Drug Administration
Investigational New Drug clearance for VY1706 in June 2026 and plans to begin dosing in a multi-site, open-label, dose-escalation clinical
trial of VY1706 in the second half of 2026.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including, without limitation,
implied and express statements about the Company’s beliefs and expectations regarding the Company’s advancement of the VY1706
program, including the timing and achievement of clinical development milestones such as the Company’s intention to initiate clinical
trials, clinical trial enrollment, and achievement of first-in-human dosing in AD in the second half of 2026 and the therapeutic potential,
safety, and pharmacological effect of VY1706. The use of words such as “may,” “will,” “might,” “would,”
“could,” “should,” “expect,” “plan,” “anticipate,” “believe,”
“potential,” “intend,” “seek,” “predict,” “estimate,” “project,”
“target,” or “continue” and other similar expressions are intended to identify forward-looking statements, although
not all forward-looking statements contain these identifying words.
All forward-looking statements are based on management’s current
estimates and assumptions and are subject to a number of risks, uncertainties, and important factors that may cause actual results to
differ materially from any forward-looking statements in this Form 8-K. Factors include, among others, the risks and uncertainties inherent
in the development of product candidates, including the initiation, enrollment, timing, cost, progress, and results of the Company’s
planned and future clinical trials; expectations and decisions of regulatory authorities; the Company’s ability to replicate positive
results from earlier preclinical studies or clinical trials in current or future clinical trials; potential adverse events the Company
may encounter that could negatively impact development; outcomes of third-party preclinical studies and clinical trials that could impact
the Company’s development plans; the Company’s ability to demonstrate that current or future product candidates are safe and
effective for their proposed indications; the Company’s scientific approach and continued development of its technology platforms,
including the TRACER and non-viral discovery platforms; the development by third parties of capsid or non-viral identification platforms
that may be competitive to its platforms and programs; the Company’s ability to create and protect its intellectual property rights;
the progress and success of programs under current or future collaboration and license agreements; the sufficiency of the Company’s
cash resources to fund its operations and pursue its corporate objectives; and technical and other unexpected hurdles in the development,
manufacture and supply of the Company’s product candidates, may delay its timing, change its plans, increase its costs, or otherwise
negatively impact its business or the sufficiency of its cash resources to fund operations.
These risks and uncertainties are described in the Company’s
most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as updated by its subsequent filings with the
Securities and Exchange Commission. All information in this Form 8-K is as of today’s date, and any forward-looking statement speaks
only as of the date on which it was made. The Company undertakes no obligation to publicly update or revise this information or any forward-looking
statement, whether as a result of new information, future events or otherwise, except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 13, 2026 |
VOYAGER THERAPEUTICS, INC. |
| |
|
| |
By: |
/s/ Alfred Sandrock, M.D., Ph.D. |
| |
|
Alfred Sandrock, M.D., Ph.D. |
| |
|
Chief Executive Officer, President, and Director
(Principal Executive Officer) |
